Skip to main content
OpenTrials
Completed

NCT Number: NCT02136589

Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes

PG-analogues induce hyperemia as one of side effects in addition to IOP reduction.

IOP reduction is caused by direct FP receptor stimulation, but the cause of hyperemia is not clarified.

Because FP receptor stimulation induce intrinsic production of PGs, hyperemia or IOP reduction may be due to secondary induced PGs.

Thus, pretreatment with NSAID may affect the PG-analogue induced hyperemia or IOP reduction.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperemia Cardiovascular Diseases Intraocular Pressure Vascular Diseases

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • normal healthy eye
  • not applicable for IOP level
  • not wearing contact lenses
  • not applicable for the presence of the ocular surface diseases in case the treatment was not needed

Exclusion criteria

  • the eyes with chronic or recurrent uveitis, scleritis, corneal herpes infection
  • the eyes with the history of trauma, intraocular surgery, or Laser surgery within 6 months
  • the eyes with difficulty for the measurement of IOP with the applanation tonometer
  • the subjects with the allergy for PG-analogues or benzalkonium chloride
  • the subjects using the eyedrops excluding those in this study
  • the subjects treated with oral carbonic anhydrase inhibitor
  • the subject with Sjogren syndrome
  • the subjects who can not drop periodically
  • the subjects with the advanced glaucoma or the terminal stage of glaucoma
  • the subjects with the severe ocular complications

Treatment and study plan

dicrofenac and travoprost

Drug

dicrofenac drop 3 times a day travoprost 0.005% once daily

Primary outcomes

  1. IOP reduction

    Time frame: 1 day

    effect of NSAID on IOP reduction by travoprost

Sponsors and collaborators

Lead sponsor

Tokyo University

Other

Registry information

Official study title

Effect of Non-steroid Anti-inflammatory Drug on Travoprost-induced Conjunctival Hyperemia and Intraocular Pressure Reduction in Normal Eyes

Acronym: ENTICHIR

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
May 13, 2014
Registry last updated
May 13, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.